Clinical trial NCT01657409 - References

Overactive Bladder — Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome

Citation(s)

•   Abrams P, Kelleher CJ, Kerr LA, Rogers RG
  Overactive bladder significantly affects quality of life. Am J Manag Care. 2000 Jul;6(11 Suppl):S580-90. Review.
•   Aoki KR
  Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003 Jul-Aug;43 Suppl 1:S9-15. Review.
•   Apostolidis A, Brady CM, Yiangou Y, Davis J, Fowler CJ, Anand P
  Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. Urology. 2005 Feb;65(2):400-5.
•   Apostolidis A, Dasgupta P, Fowler CJ
  Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006 Apr;49(4):644-50. Review.
•   Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, Dasgupta P, Fowler CJ, Anand P
  Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005 Sep;174(3):977-82; discussion 982-3.
•   Atiemo H, Wynes J, Chuo J, Nipkow L, Sklar GN, Chai TC
  Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model. Urology. 2005 Mar;65(3):622-6.
•   Avelino A, Cruz F
  TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol. 2006 Jul;373(4):287-99. Review.
•   Birder LA
  More than just a barrier: urothelium as a drug target for urinary bladder pain. Am J Physiol Renal Physiol. 2005 Sep;289(3):F489-95. Review.
•   Brady CM, Apostolidis A, Yiangou Y, Baecker PA, Ford AP, Freeman A, Jacques TS, Fowler CJ, Anand P
  P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol. 2004 Aug;46(2):247-53.
•   Brady CM, Apostolidis AN, Harper M, Yiangou Y, Beckett A, Jacques TS, Freeman A, Scaravilli F, Fowler CJ, Anand P
  Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int. 2004 Apr;93(6):770-6.
•   Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J; Pelvic Floor Disorders Network
  . Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008 Jul;180(1):217-22. doi: 10.1016/j.juro.2008.03.028.
•   Chen GD, Lin TL, Hu SW, Chen YC, Lin LY
  Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women. Neurourol Urodyn. 2003;22(2):109-17.
•   Chuang YC, Lee WC, Lee WC, Chiang PH
  Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol. 2009 Oct;182(4):1393-400. doi: 10.1016/j.juro.2009.06.024.
•   Chuang YC, Tyagi P, Huang CC, Yoshimura N, Wu M, Kaufman J, Chancellor MB
  Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol. 2009 Aug;182(2):786-92. doi: 10.1016/j.juro.2009.03.083.
•   Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB
  Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol. 2004 Oct;172(4 Pt 1):1529-32.
•   Crowley SL, Worchel FF, Ash MJ
  Self-report, peer-report, and teacher-report measures of childhood depression: an analysis by item. J Pers Assess. 1992 Aug;59(1):189-203.
•   Cui M, Aoki KR
  Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalalgia 20:414-8, 2000.
•   Dumoulin C, Hay-Smith J
  Pelvic floor muscle training versus no treatment for urinary incontinence in women. A Cochrane systematic review. Eur J Phys Rehabil Med. 2008 Mar;44(1):47-63. Review.
•   Egerdie RB, Reid G, Trachtenberg J
  The effect of liposome encapsulated antineoplastic agents on transitional cell carcinoma in tissue culture. J Urol. 1989 Aug;142(2 Pt 1):390-8.
•   Fraser MO, Chuang YC, Tyagi P, Yokoyama T, Yoshimura N, Huang L, De Groat WC, Chancellor MB
  Intravesical liposome administration--a novel treatment for hyperactive bladder in the rat. Urology. 2003 Mar;61(3):656-63.
•   Ghei M, Maraj BH, Miller R, Nathan S, O'Sullivan C, Fowler CJ, Shah PJ, Malone-Lee J
  Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol. 2005 Nov;174(5):1873-7; discussion 1877.
•   Giannantoni A, Di Stasi SM, Chancellor MB, Costantini E, Porena M
  New frontiers in intravesical therapies and drug delivery. Eur Urol. 2006 Dec;50(6):1183-93; discussion 1193. Review.
•   Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E
  Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol. 2008 Mar;179(3):1031-4. doi: 10.1016/j.juro.2007.10.032.
•   Homma Y, Yamaguchi O, Hayashi K; Neurogenic Bladder Society Committee
  . An epidemiological survey of overactive bladder symptoms in Japan. BJU Int. 2005 Dec;96(9):1314-8.
•   Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L
  Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006 Jan;97(1):96-100.
•   Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC
  Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn. 2005;24(3):231-6.
•   Kullmann FA, Artim DE, Birder LA, de Groat WC
  Activation of muscarinic receptors in rat bladder sensory pathways alters reflex bladder activity. J Neurosci. 2008 Feb 20;28(8):1977-87. doi: 10.1523/JNEUROSCI.4694-07.2008.
•   Kuo HC, Liu HT, Yang WC
  Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study. J Urol. 2006 Aug;176(2):641-5.
•   Kuo HC
  Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology. 2005 Jul;66(1):94-8.
•   Kuo HC
  Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology. 2004 May;63(5):868-72.
•   Liu HT, Chancellor MB, Kuo HC
  Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol. 2009 Oct;56(4):700-6. doi: 10.1016/j.eururo.2008.04.037.
•   Liu HT, Kuo HC
  Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology. 2007 Sep;70(3):463-8.
•   Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ
  How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 Jun;87(9):760-6. Erratum in: BJU Int 2001 Nov;88(7):807.
•   Mukerji G, Yiangou Y, Grogono J, Underwood J, Agarwal SK, Khullar V, Anand P
  Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol. 2006 Jul;176(1):367-73.
•   Ouslander JG
  Management of overactive bladder. N Engl J Med. 2004 Feb 19;350(8):786-99. Review.
•   Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P
  A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005 Sep;174(3):984-9.
•   Rajkumar GN, Small DR, Mustafa AW, Conn G
  A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int. 2005 Oct;96(6):848-52.
•   Reimer K, Fleischer W, Brögmann B, Schreier H, Burkhard P, Lanzendörfer A, Gümbel H, Hoekstra H, Behrens-Baumann W
  Povidone-iodine liposomes--an overview. Dermatology. 1997;195 Suppl 2:93-9. Review.
•   Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdörfer H, Göcking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B
  European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004 Apr;45(4):510-5.
•   Sahai A, Khan MS, Dasgupta P
  Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007 Jun;177(6):2231-6.
•   Sahai A, Sangster P, Kalsi V, Khan MS, Fowler CJ, Dasgupta P
  Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable? BJU Int. 2009 Mar;103(5):630-4. doi: 10.1111/j.1464-410X.2008.08076.x.
•   Schulte-Baukloh H, Weiss C, Stolze T, Stürzebecher B, Knispel HH
  Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology. 2005 Jul;66(1):82-7.
•   Simpson LL
  Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther. 1980 Jan;212(1):16-21.
•   Smet PJ, Moore KH, Jonavicius J
  Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab Invest. 1997 Jul;77(1):37-49.
•   Sui GP, Rothery S, Dupont E, Fry CH, Severs NJ
  Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int. 2002 Jul;90(1):118-29.
•   Truschel ST, Wang E, Ruiz WG, Leung SM, Rojas R, Lavelle J, Zeidel M, Stoffer D, Apodaca G
  Stretch-regulated exocytosis/endocytosis in bladder umbrella cells. Mol Biol Cell. 2002 Mar;13(3):830-46.
•   Tyagi P, Chancellor MB, Li Z, De Groat WC, Yoshimura N, Fraser MO, Huang L
  Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J Urol. 2004 Jan;171(1):483-9.
•   Tyagi P, Wu PC, Chancellor M, Yoshimura N, Huang L
  Recent advances in intravesical drug/gene delivery. Mol Pharm. 2006 Jul-Aug;3(4):369-79. Review.
•   Vemulakonda VM, Somogyi GT, Kiss S, Salas NA, Boone TB, Smith CP
  Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation. J Urol. 2005 Feb;173(2):621-4.
•   Wang E, Truschel S, Apodaca G
  Analysis of hydrostatic pressure-induced changes in umbrella cell surface area. Methods. 2003 Jul;30(3):207-17.
•   White WM, Pickens RB, Doggweiler R, Klein FA
  Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol. 2008 Dec;180(6):2522-6. doi: 10.1016/j.juro.2008.08.030.
•   Wiseman OJ, Fowler CJ, Landon DN
  The role of the human bladder lamina propria myofibroblast. BJU Int. 2003 Jan;91(1):89-93.
•   Yiangou Y, Facer P, Ford A, Brady C, Wiseman O, Fowler CJ, Anand P
  Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. BJU Int. 2001 Jun;87(9):774-9.
•   Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A
  Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology. 2004 Mar;63(3 Suppl 1):17-23. Review.

Comparison of the Therapeutic Effects of Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome

Details for clinical trial NCT01657409